Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886948 | 0.92 | POLB (0.44) | SMN1; SMN2MEN1KMT2AMAPTGFER | |
| SCHEMBL5886875 | 0.91 | SMN1; SMN2 (0.41) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5887195 | 0.90 | EPHX2 (0.44) | ENPP2RORCSMN1; SMN2KMT2AMAPT | |
| SCHEMBL5886763 | 0.88 | SMN1; SMN2 (0.42) | BRAFENPP2SMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL5886791 | 0.88 | ENPP2 (0.48) | BRAFENPP2SMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL5887513 | 0.87 | GFER (0.43) | ENPP2SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL5886867 | 0.86 | BRAF (0.48) | BRAFCYP2C19KMT2AMAPK14 | |
| SCHEMBL5887138 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2C19KMT2AMAPTGFER | |
| SCHEMBL5887410 | 0.86 | SMN1; SMN2 (0.46) | BRAFENPP2SMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL5886889 | 0.85 | MAPK10 (0.45) | BRAFENPP2SMN1; SMN2MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | BRAF 1390/4885ENPP2 3051/4885RORC 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.